# Perifosine in Treating Patients With Recurrent Prostate Cancer

> **NCT00058214** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer
- Stage IIB Prostate Cancer
- Stage III Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** perifosine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00058214
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Did not meet interim stopping criteria for continuation to the second stage.
- **Last updated:** 2015-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058214, "Perifosine in Treating Patients With Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00058214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*